Literature DB >> 11471893

Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women.

M V Croce1, M T Isla-Larrain, M R Price, A Segal-Eiras.   

Abstract

There is convincing epidemiological evidence that multiparity provides protection against the development of breast cancer. In the present study we evaluated the levels of MUC1 and MUC1 circulating immune complexes (MUC1-CIC) in 135 serum samples obtained from healthy women. The study population included 13 women who had never been pregnant, 31 primiparous pregnant women, 36 multiparous pregnant women who had lactated, 5 multiparous pregnant women who had never lactated, 24 multiparous non-pregnant women who were lactating at the time of the study, 24 multiparous non-pregnant women who had lactated, and 2 multiparous non-pregnant women who had never lactated. The purpose of this work was to detect MUC1 variations during pregnancy and lactation as well as to study the possible induction of a humoral immune response against MUC1 in these conditions. We employed ELISA techniques to measure MUC1 (CASA test) and MUC1-CIC (IgM and IgG) using two anti-MUC1 monoclonal antibodies (MAbs): C595 and SM3. Statistical analysis was performed using the ANOVA test. The pooled results pertaining to pregnant versus non-pregnant women were compared and significant differences were observed in MUC1 and MUC1-CIC-lgM levels detected with both MAbs; the MUC1-CIC-lgG levels detected with C595 were increased in the pregnant group while the MUC1-CIC-lgG levels detected with SM3 did not show any significant differences. When the results were compared between lactating and non-lactating women, no significant differences were found. In conclusion, MUC1 and MUC1-CIC-lgM, detected with both MAbs, and MUC1-CIC-4gG levels detected with the MAb C595 are apparently induced by pregnancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471893     DOI: 10.1177/172460080101600205

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  10 in total

1.  Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.

Authors:  Simone P Pinheiro; Susan E Hankinson; Shelley S Tworoger; Bernard A Rosner; John R McKolanis; Olivera J Finn; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Periodontal bone loss and risk of epithelial ovarian cancer.

Authors:  Ana Babic; Elizabeth M Poole; Kathryn L Terry; Daniel W Cramer; Ricardo P Teles; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2015-04-03       Impact factor: 2.506

3.  Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.

Authors:  Yan Tang; Li Wang; Peiyin Zhang; Hongfei Wei; Rui Gao; Xinming Liu; Yongli Yu; Liying Wang
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

4.  Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study.

Authors:  Megan S Rice; Megan A Murphy; Allison F Vitonis; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Int J Cancer       Date:  2013-07-09       Impact factor: 7.396

5.  Autoantibodies to mesothelin in infertility.

Authors:  Judith L Luborsky; Yi Yu; Seby L Edassery; Jade Jaffar; Yuan Yee Yip; Pu Liu; Karl Eric Hellstrom; Ingegerd Hellstrom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-08-16       Impact factor: 4.254

6.  Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature.

Authors:  Sandra O Demichelis; Marina T Isla-Larrain; Luciano Cermignani; Cecilio G Alberdi; Amada Segal-Eiras; María Virginia Croce
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-12-20

7.  Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients.

Authors:  Carlo Fremd; Stefan Stefanovic; Philipp Beckhove; Maria Pritsch; Hendry Lim; Markus Wallwiener; Joerg Heil; Michael Golatta; Joachim Rom; Christof Sohn; Andreas Schneeweiss; Florian Schuetz; Christoph Domschke
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

8.  Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.

Authors:  M V Croce; M Isla-Larrain; R Tur; M E Rabassa; A Segal-Eiras
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  A mouse monoclonal antibody against influenza C virus attenuates acetaminophen-induced liver injury in mice.

Authors:  Yutaka Sasaki; Naoto Yoshino; Takako Okuwa; Takashi Odagiri; Takashi Satoh; Yasushi Muraki
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

10.  Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study.

Authors:  Ebru Menekse; John McKolanis; Olivera J Finn; Priscilla F McAuliffe; Ronald Johnson; Atilla Soran
Journal:  Dis Markers       Date:  2015-11-29       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.